Skip to main content
Fig. 5 | BMC Nephrology

Fig. 5

From: Guidelines adherence in the prevention and management of chronic kidney disease in patients with diabetes mellitus on the background of recent European recommendations – a registry-based analysis

Fig. 5

Proportion of patients using GLP-1 RAs as per guideline recommendation. Legend: Treatment with the GLP1-RAs liraglutide and semaglutide is associated with a lower risk of renal endpoints, and should be considered* for DM treatment if eGFR is > 30 mL/min/1.73 m2 [3]. Analyses restricted to the last treatment year; values are percent with 95 % CIs; *Although evidence is not available for patients with T1DM

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us